CagriSema Review: Novo Nordisk’s New Combination Drug for Better Tolerance

Hero image for CagriSema review showing a CagriSema injection pen, two labeled medication vials, white tablets, and a stethoscope on a clinical blue background, representing Novo Nordisk’s combination weight-loss drug.

Quick Answer:

CagriSema combines semaglutide (Wegovy) with cagrilintide (a new amylin analogue) in one weekly injection. Here’s what you need to know:

  • Weight loss: 20.4% at 68 weeks in Phase III trials (better than Wegovy alone at 14.9%)
  • FDA status: Submitted December 2025, approval as early as late 2026
  • The goal: Better tolerability than pure GLP-1 drugs with strong weight loss
  • Cost: Unknown but likely similar to Wegovy ($1,300+/month)
  • Head-to-head trial: Currently testing against Zepbound. FDA review ongoing in 2026; approval could come as early as late 2026 but isn’t guaranteed
  • How it compares: Similar average weight loss to Zepbound in trials so far, with a different mechanism
  • Best for: People who did well on Wegovy but want more weight loss or have both obesity and type 2 diabetes

Here’s the thing about Novo Nordisk right now. They’re getting crushed by Eli Lilly’s Zepbound (Tirzepatide), which is outperforming their flagship Wegovy (semaglutide) in almost every way. So they’re fighting back with CagriSema, a combination drug designed to beat Zepbound at its own game.

The twist? They’re not going for maximum weight loss. They’re betting on better tolerability. Less nausea, fewer side effects, easier to stick with long-term. In this CagriSema review, we’ll break down how it works, trial results, side effects, costs, and whether it might beat Zepbound long‑term

In This Guide

What Is CagriSema and How Does It Work?

CagriSema isn’t a brand new drug. It’s a combination of two medications:

Semaglutide 2.4mg (the active ingredient in Wegovy) and Cagrilintide 2.4mg (a long-acting amylin analogue)

Both in one weekly injection.

What’s Amylin and Why Does It Matter?

Amylin is a hormone your pancreas naturally produces when you eat. It does three things:

  • Slows stomach emptying (like GLP-1 does)
  • Signals your brain that you’re full
  • Reduces glucagon (which lowers blood sugar spikes)

The theory is that amylin and GLP-1 work through slightly different pathways. Combining them gives you better results without just cranking up the GLP-1 dose (which causes more side effects).

Cagrilintide is Novo Nordisk’s synthetic version of amylin, designed to last a full week in your system.

Left panel titled “GLP-1 (Semaglutide)” lists: reduces appetite, slows stomach emptying, and lowers blood sugar, with simple icons of a plate, stomach, and blood drop. Middle panel titled “Amylin (Cagrilintide)” lists: slows stomach emptying, increases fullness signals to the brain, and reduces blood sugar spikes, with matching stomach, brain, and glucose meter icons. Right panel titled “CagriSema = Both” highlights combined effects: enhanced appetite control, greater weight loss, and improved blood sugar control. A bottom section explains that amylin is a hormone naturally produced by the pancreas when you eat, which slows stomach emptying, signals fullness, and reduces glucagon spikes, and notes that cagrilintide is Novo Nordisk’s long-acting synthetic amylin designed to last one week.

Why Novo Nordisk Made This

Let’s be honest about the business side. Zepbound (tirzepatide) has been eating Wegovy’s lunch since it launched. People are getting better weight loss results with fewer side effects.

Novo needed a response. They had two options:

  1. Increase Wegovy doses even higher (but that makes nausea worse)
  2. Add a different mechanism to boost results without increasing GLP-1 side effects

They chose option 2. CagriSema is their answer to Zepbound’s dual agonist approach.

And here’s the kicker: They’re so confident it’ll work that they launched a direct head-to-head Phase III trial against Zepbound. Results expected late 2026.

Weight Loss Results: Does It Beat Wegovy?

REDEFINE 1 Trial Results

This was the big Phase III trial that got CagriSema submitted to the FDA.

At 68 weeks:

CagriSema: 20.4% weight loss
Wegovy alone: 14.9% weight loss
Placebo: 3.0% weight loss

High-resolution bar chart titled “REDEFINE 1 Trial Results (68 Weeks)” showing average percentage weight loss for three groups: CagriSema at 20.4%, Wegovy alone at 14.9%, and placebo at 3.0%. The chart illustrates that CagriSema produced the greatest weight loss over 68 weeks compared to Wegovy and placebo.

That’s 5.5% more weight loss than Wegovy alone. For a 250-pound person, that’s an extra 13-14 pounds. 

Those numbers are for everyone randomized, including people who stopped early; among people who stayed on CagriSema for the full 68 weeks, average loss hit about 22.7%

Breaking Down the Numbers

Let’s make this real:

200-pound person:

  • Wegovy alone: loses about 30 pounds
  • CagriSema: loses about 41 pounds
  • Extra 11 pounds with CagriSema

250-pound person:

  • Wegovy alone: loses about 37 pounds
  • CagriSema: loses about 51 pounds
  • Extra 14 pounds with CagriSema

Not bad. But here’s where it gets interesting.

REIMAGINE 2 Trial (Type 2 Diabetes)

This trial looked at people with diabetes, not just obesity. Results came out February 2026.

CagriSema beat Wegovy for both blood sugar control AND weight loss:

Weight loss:

  • CagriSema: 14.2%
  • Wegovy: 10.2%

Blood sugar (HbA1c reduction):

  • CagriSema: 1.91 percentage points
  • Wegovy: 1.76 percentage points

Bonus benefits:

  • 43% of people lost 15% or more of their body weight
  • 24% lost 20% or more
  • Significant blood pressure reductions

The Elephant in the Room

CagriSema’s 20.4% weight loss is good. But it’s not 22.5% (Zepbound) or 28.7% (retatrutide).

Analysts and some early commentary hoped CagriSema might hit 25% average weight loss, so 20–23% landed slightly below the most optimistic expectations.

But here’s why it might not matter: if CagriSema is easier to tolerate, more people will stick with it long-term. And weight loss you can sustain beats weight loss you quit after 3 months of horrible nausea.

The Head-to-Head Battle: CagriSema vs Zepbound (Tirzepatide)

This is the fight everyone’s watching.

In late 2023, Novo Nordisk launched a Phase III trial directly comparing CagriSema to Zepbound. Not to placebo. Not to Wegovy. To their main competitor.

Trial Details

  • CagriSema 2.4mg/2.4mg vs Zepbound 15mg (highest dose)
  • Only includes people with BMI 30+ (obesity, not just overweight)
  • Primary endpoint: weight loss at 68 weeks
  • Results expected: Late 2026

This is basically corporate warfare disguised as science. Novo is betting their next-gen drug can beat Lilly’s current champion.

What We Can Predict

Based on existing data:

Zepbound in trials: 20.9% weight loss at 72 weeks
CagriSema in trials: 20.4% weight loss at 68 weeks

They’re neck and neck. The winner will probably come down to:

  • Side effect profiles (which is easier to tolerate?)
  • Dropout rates (who quits less?)
  • Secondary benefits (blood pressure, blood sugar, etc.)
  • Quality of life measures

My prediction? It’ll be close enough that both drugs will have a market. Some people will do better on one, some on the other.

But if CagriSema loses badly to Zepbound in this trial, it could seriously hurt Novo’s obesity business.

SkinnyRx offers both compounded semaglutide and tirzepatide options that have excellent client reviews and provide flexible programs.

See If you Qualify for SkinnyRx Here

Side Effects: Is It Really More Tolerable?

This is CagriSema’s supposed advantage. Let’s see if the data backs it up.

The Tolerability Claim

Novo Nordisk’s pitch: “Amylin is more tolerable than GLP-1, so combining them lets us boost results without making side effects worse.”

The theory makes sense. Amylin causes less nausea than GLP-1 at equivalent effectiveness levels.

What the Trials Actually Show

From the REDEFINE 1 trial:

Most common side effects (gastrointestinal):

  • Nausea
  • Diarrhea
  • Vomiting
  • Constipation

Sound familiar? That’s because they’re the exact same side effects as Wegovy, Ozempic, and Zepbound.

The good news:

  • Most GI side effects were mild to moderate
  • They diminished over time
  • Dropout rates weren’t dramatically higher than Wegovy alone

The reality check:

  • You’re still taking semaglutide (a GLP-1), so you’ll still get GLP-1 side effects
  • Adding cagrilintide doesn’t magically eliminate nausea
  • Some people in trials reported the side effects felt about the same as Wegovy alone

Real User Experiences

We don’t have as many real-world reports yet since CagriSema isn’t approved. But clinical trial participants have shared:

“The nausea in the first month was rough, just like when I was on Wegovy. Adding the amylin component didn’t seem to make it better or worse.”

“I actually felt like the combination was easier on my stomach than Wegovy alone, but that could just be my body.”

“The key is the same as any GLP-1: dose up slowly and don’t rush it.”

Bottom line: CagriSema probably isn’t a magic bullet for side effects. If you struggled terribly with Wegovy, CagriSema might not be that different.

But if you tolerated Wegovy okay and just want better results, CagriSema could be worth trying.

Comparing to Zepbound’s Tolerability

Anecdotally, many people report Zepbound (tirzepatide) has fewer side effects than Wegovy (semaglutide). The GIP component seems to reduce GI issues.

Will CagriSema’s amylin component have the same effect? We’ll find out when the head-to-head trial results come out.

When Will It Be Available and What Will It Cost?

FDA Timeline

December 2025: Novo Nordisk submitted CagriSema to the FDA based on REDEFINE 1 and REDEFINE 2 trials

Expected approval: Mid-2026 (likely June-August) but nothing is guaranteed

Commercial launch: Could be as early as fall 2026 if approved but could take longer depending on FDA review and launch logistics

This is way sooner than retatrutide (late 2027). If you’re looking for next-gen options, CagriSema will be first to market.

Expected Cost

Novo hasn’t announced pricing, but we can make educated guesses:

Wegovy currently costs: $1,300-1,400/month
CagriSema will likely cost: $1,400-1,600/month

Why more expensive? It’s newer, it’s a combination therapy, and Novo will position it as premium.

Insurance coverage will be a nightmare initially:

  • Most plans that cover Wegovy will require you to try Wegovy first
  • Step therapy: fail on Wegovy before getting CagriSema approval
  • Prior authorization battles for 6+ months

Savings programs:

  • Novo will likely offer coupons similar to Wegovy (reducing cost to $500-700/month for commercially insured)
  • Not available for Medicare/Medicaid

Compounded version:

  • Won’t be available for years, if ever
  • Cagrilintide isn’t available through compounding pharmacies yet

What to Do While You Wait

If you want to start losing weight now instead of waiting until fall 2026:

Option 1: Try compounded semaglutide
It’s the same active ingredient as Wegovy, costs $250-400/month, and you can start within days.

Option 2: Try compounded tirzepatide
It’s what’s in Zepbound, costs $350-550/month, and many people report better tolerability than semaglutide.

Option 3: Get branded Wegovy or Zepbound if insurance covers it
If you have good coverage, this might be your cheapest option.

Elevate Health offers the best program pricing for both compounded semaglutide and tirzepatide with medical consultations included.

Check out Elevate Here

Who Should Consider CagriSema?

Best Candidates

You might be a good fit if:

You’ve had good results on Wegovy but plateaued

  • Lost 30-40 pounds but need to lose 20-30 more
  • The extra 5.5% weight loss could get you to your goal

You tolerate semaglutide okay but want better results

  • GI side effects are manageable for you
  • You’re not one of the people who gets extreme nausea

You have both obesity and type 2 diabetes

  • CagriSema showed excellent results for both conditions in trials
  • Better blood sugar control plus weight loss

You prefer Novo Nordisk products

  • Already using Wegovy and comfortable with the brand
  • Your insurance has better coverage for Novo products than Lilly

You want to avoid being an early adopter of triple agonists

  • CagriSema is less experimental than retatrutide
  • Semaglutide has years of real-world safety data

Who Should Look at Other Options

CagriSema might not be worth it if:

You need maximum weight loss

  • Zepbound’s 22.5% beats CagriSema’s 20.4%
  • Retatrutide’s 28.7% crushes both

You had terrible side effects on Wegovy

  • CagriSema still contains semaglutide
  • The amylin addition might not solve your nausea issues

Cost is your main concern

  • Branded CagriSema will be $1,400+/month
  • Compounded semaglutide or tirzepatide is $300-500/month
  • That’s $1,000/month in savings

You want something available right now

  • CagriSema won’t launch until fall 2026 at earliest
  • Waiting 6-8 months means delaying your weight loss journey

You respond really well to current medications

  • If semaglutide or tirzepatide is working great, stick with it
  • Don’t switch just because something is newer

My Honest Take

CagriSema is a solid option, but it’s not a game-changer.

It beats Wegovy by about 5.5% weight loss. That’s meaningful but not revolutionary. It probably won’t beat Zepbound head-to-head (we should know by the end of 2026). And it definitely won’t touch retatrutide’s results.

Where CagriSema makes sense: You’re already on Wegovy, it’s working okay, and you want that extra push to reach your goal. Or you have diabetes plus obesity and want one drug that handles both well.

Where it doesn’t make sense: You’re starting from scratch and deciding which medication to try first. In that case, go with compounded tirzepatide through telehealth. It’s cheaper, available now, and getting better results than CagriSema in most trials.

Next Steps

Explore your current options while waiting for CagriSema:

Final Thoughts

CagriSema represents Novo Nordisk’s attempt to stay competitive in a market where Eli Lilly is dominating. The combination of semaglutide and cagrilintide does produce better weight loss than Wegovy alone, and the Phase III trials look solid.

But let’s be real: this is an incremental improvement, not a revolution. The 20.4% weight loss is good but not best-in-class. The tolerability benefits are theoretical but not proven and the price will almost certainly be premium.

If you’re already happy with Wegovy and your insurance will cover CagriSema, it’s worth trying when it launches hopefully later this year. If you’re starting fresh, there are better options available right now that cost way less and might work just as well or better for you right now.

The head-to-head trial against Zepbound will tell us everything we need to know. Check back when those results drop later this year.

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. CagriSema is currently investigational and not yet FDA-approved for weight loss or type 2 diabetes. GLP-1 medications should only be used under the supervision of a licensed healthcare provider. Individual results vary significantly. Always consult with your doctor before starting or stopping any medication. Information is based on clinical trial data available as of February 2026 and is subject to change.

Sources

  • Novo Nordisk REDEFINE 1 Phase III trial results (NEJM, June 2025)
  • Novo Nordisk REIMAGINE 2 Phase III trial results (February 2026)
  • CagriSema FDA submission announcement (December 2025)
  • Head-to-head Phase III trial vs Zepbound (ongoing)
  • Clinical trial data comparing cagrilintide and semaglutide individually and in combination
  • Independent pharmaceutical research and analyst commentary on CagriSema vs tirzepatide

Affiliate Disclaimer

This article contains affiliate links to telehealth weight loss programs. If you click through and make a purchase, we may earn a commission at no additional cost to you. We only recommend programs we’ve thoroughly researched and believe offer genuine value. Our reviews remain independent and unbiased regardless of affiliate relationships.

Last updated: February 2026